Drug Profile
Research programme: RNA interference-based therapeutics - NuGenerex Immuno-Oncology
Alternative Names: Ii suppression - NuGenerex Immuno-OncologyLatest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Antigen Express
- Developer NuGenerex Immuno-Oncology
- Class DNA vaccines; Small interfering RNA
- Mechanism of Action Helper-inducer T-lymphocyte stimulants; Invariant chain inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
- 01 Jan 2011 Preclinical trials in HIV infections in USA (Parenteral)